Literature DB >> 23422917

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

B J Werth1, C Vidaillac, K P Murray, K L Newton, G Sakoulas, P Nonejuie, J Pogliano, M J Rybak.   

Abstract

We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively. Beta-lactam exposure reduced overall vancomycin-Bodipy (dipyrromethene boron difluoride [4,4-difluoro-4-bora-3a,4a-diaza-s-indacene] fluorescent dye) binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23422917      PMCID： PMC3632910          DOI： 10.1128/AAC.02354-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

2.  A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation.

Authors:  J Pogliano; N Osborne; M D Sharp; A Abanes-De Mello; A Perez; Y L Sun; K Pogliano
Journal:  Mol Microbiol       Date:  1999-02       Impact factor: 3.501

Review 3.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods.

Authors:  F W Goldstein; R Atoui; A Ben Ali; J C Nguyen; A Ly; M D Kitzis
Journal:  Clin Microbiol Infect       Date:  2004-04       Impact factor: 8.067

Review 5.  The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.

Authors:  P C Appelbaum
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

6.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

Review 8.  The escalating challenge of vancomycin resistance in Staphylococcus aureus.

Authors:  R F Pfeltz; B J Wilkinson
Journal:  Curr Drug Targets Infect Disord       Date:  2004-12

9.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

10.  Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Authors:  Steven N Leonard; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191
View more
  20 in total

1.  Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-02-15       Impact factor: 2.649

2.  Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  Brian J Werth
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

3.  Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels.

Authors:  Kelly M Hines; Tianwei Shen; Nathaniel K Ashford; Adam Waalkes; Kelsi Penewit; Elizabeth A Holmes; Kathryn McLean; Stephen J Salipante; Brian J Werth; Libin Xu
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

4.  Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.

Authors:  Masayuki Nigo; Lorena Diaz; Lina P Carvajal; Truc T Tran; Rafael Rios; Diana Panesso; Juan D Garavito; William R Miller; Audrey Wanger; George Weinstock; Jose M Munita; Cesar A Arias; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Antibiofilm and membrane-damaging potential of cuprous oxide nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Avinash Singh; Asar Ahmed; Kashi N Prasad; Sonali Khanduja; Satyendra K Singh; Janmejai K Srivastava; Namdeo S Gajbhiye
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.191

6.  Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.

Authors:  Xuting Zheng; Andrew D Berti; Sue McCrone; Melanie Roch; Adriana E Rosato; Warren E Rose; Baiyi Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.

Authors:  Thomas J Dilworth; Omar Ibrahim; Pamela Hall; Jora Sliwinski; Carla Walraven; Renée-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

8.  Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Brian J Werth; Katie E Barber; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

9.  Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Authors:  Jordan R Smith; Juwon Yim; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

10.  Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.

Authors:  Hilary M Teibel; Chad A Knoderer; Kristen R Nichols
Journal:  Hosp Pharm       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.